Gene Expression Profiling to Predict the Risk of Locoregional Recurrence in Breast Cancer: A Pooled Analysis

PUBLICATION: Breast Cancer Res Treat (2014) 148: 599. https://doi.org/10.1007/s10549-014-3188-z. AUTHORS: Read More

2024-03-25T09:27:24-07:00November 24th, 2014|Adjuvant, Evidence, MammaPrint|

Genomic Profile of Breast Cancer: Cost-Effectiveness Analysis from the Spanish National Healthcare System Perspective

PUBLICATION: Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):889-99. doi: 10.1586/14737167.2014.957185. Read More

2024-03-25T11:22:23-07:00September 12th, 2014|Evidence, Healthcare Economics, MammaPrint, Other|

Molecular Subtyping Predicts Pathologic Tumor Response in Early-Stage Breast Cancer Treated with Neoadjuvant Docetaxel Plus Capecitabine with or without Trastuzumab Chemotherapy

PUBLICATION: Med Oncol. (2014) 31: 163. https://doi.org/10.1007/s12032-014-0163-9. AUTHORS: Soley Bayraktar, Read More

2024-03-25T10:18:35-07:00September 4th, 2014|BluePrint, Evidence, Neoadjuvant|

The Multigene Signature MammaPrint Impacts on Multidisciplinary Team Decisions in ER+, HER2− Early Breast Cancer

PUBLICATION: British Journal of Cancer, volume 111, pages 837–842 (26 Read More

2024-03-25T10:20:39-07:00August 26th, 2014|Adjuvant, Evidence, MammaPrint|

Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

PUBLICATION: Annals of Surgical Oncology; October 2014, Volume 21, Issue Read More

2024-02-20T10:41:05-08:00August 7th, 2014|Evidence, NBRST, Neoadjuvant|
Go to Top